Atea Financial Statements From 2010 to 2026

AVIR Stock  USD 3.41  0.07  2.01%   
Atea Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Atea Pharmaceuticals' valuation are provided below:
Gross Profit
-120.1 M
Market Capitalization
266.4 M
Enterprise Value Revenue
58.974
Revenue
192.2 M
Earnings Share
(1.77)
There are over one hundred nineteen available fundamental signals for Atea Pharmaceuticals, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to validate Atea Pharmaceuticals' prevailing fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 01/08/2026, Market Cap is likely to drop to about 308.4 M. In addition to that, Enterprise Value is likely to drop to about 239.5 M

Atea Pharmaceuticals Total Revenue

192.18 Million

Check Atea Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Atea Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 30.8 M, Interest Income of 30.8 M or Depreciation And Amortization of 502.3 K, as well as many indicators such as Price To Sales Ratio of 2.3, Dividend Yield of 0.0 or PTB Ratio of 0.7. Atea financial statements analysis is a perfect complement when working with Atea Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Atea Stock
Check out the analysis of Atea Pharmaceuticals Correlation against competitors.
To learn how to invest in Atea Stock, please use our How to Invest in Atea Pharmaceuticals guide.

Atea Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets537.4 M534.4 M280.6 M
Slightly volatile
Other Current Liabilities19.7 M15.3 M10.1 M
Slightly volatile
Total Current Liabilities15.9 M16.7 M29 M
Pretty Stable
Other Liabilities6.3 MM2.1 M
Slightly volatile
Property Plant And Equipment Net1.5 M2.4 M826.8 K
Slightly volatile
Accounts Payable2.6 M5.1 M1.6 M
Slightly volatile
Cash70.7 M74.4 M173.3 M
Slightly volatile
Non Current Assets Total2.1 M2.7 M1.2 M
Slightly volatile
Non Currrent Assets Other215.2 K226.6 K289.3 K
Slightly volatile
Other Assets1.091.15197.1 K
Pretty Stable
Cash And Short Term Investments526.5 M522.9 M275 M
Slightly volatile
Common Stock Total Equity50.9 K95.5 K38.8 K
Slightly volatile
Common Stock Shares Outstanding80.8 M96.9 M45.5 M
Slightly volatile
Liabilities And Stockholders Equity537.4 M534.4 M280.6 M
Slightly volatile
Non Current Liabilities Total6.2 M6.5 M43.1 M
Slightly volatile
Other Current Assets7.9 M8.8 MM
Slightly volatile
Other Stockholder Equity554.7 M923.2 M296.5 M
Slightly volatile
Total Liabilities22.1 M23.2 M72.1 M
Pretty Stable
Property Plant And Equipment Gross3.9 M3.7 M1.2 M
Slightly volatile
Total Current Assets535.3 M531.7 M279.5 M
Slightly volatile
Capital Stock68.4 K96.6 K40 K
Slightly volatile
Non Current Liabilities Other7.2 M6.8 M2.3 M
Slightly volatile
Net Working Capital465.1 M510.3 M247 M
Slightly volatile
Common Stock68.4 K96.6 K40 K
Slightly volatile
Property Plant Equipment4.9 M4.7 M1.3 M
Slightly volatile
Net Receivables4.7 M5.2 M5.7 M
Slightly volatile
Capital Surpluse696.8 M752.1 M635.7 M
Slightly volatile
Short and Long Term Debt TotalM1.9 M790.9 K
Slightly volatile
Capital Lease ObligationsM1.9 M790.9 K
Slightly volatile

Atea Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income30.8 M29.3 M7.7 M
Slightly volatile
Interest Income30.8 M29.3 M7.7 M
Slightly volatile
Depreciation And Amortization502.3 K478.4 K134.7 K
Slightly volatile
Selling General Administrative34.9 M56.2 M19.7 M
Slightly volatile
Other Operating Expenses123.3 M221.9 M70.9 M
Slightly volatile
Research Development91.5 M167.2 M52.6 M
Slightly volatile
Cost Of Revenue100.7 M95.9 M22.9 M
Slightly volatile
Total Operating Expenses93.2 M126 M52.2 M
Slightly volatile
Reconciled Depreciation502.3 K478.4 K134.7 K
Slightly volatile
Total Other Income Expense Net30.8 M29.3 M7.7 M
Slightly volatile
Non Operating Income Net Other162.8 K244.9 K127.8 K
Slightly volatile
Selling And Marketing Expenses39.6 M44.5 M48.6 M
Slightly volatile

Atea Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation30.8 M59.5 M17 M
Slightly volatile
Begin Period Cash Flow317.2 M165.4 M154.2 M
Slightly volatile
Depreciation502.3 K478.4 K134.7 K
Slightly volatile
Issuance Of Capital Stock196.7 K207 K52.3 M
Very volatile
End Period Cash Flow55.3 M58.2 M144.6 M
Slightly volatile
Change To Netincome49.8 M47.4 M16 M
Slightly volatile
Sale Purchase Of Stock1.3 M1.3 M344.6 M
Slightly volatile
Change To Inventory4.1 M4.6 M5.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.32.4246.5985
Slightly volatile
Days Sales Outstanding34.9139.2842.8724
Slightly volatile
Stock Based Compensation To Revenue0.140.130.1416
Slightly volatile
Capex To Depreciation7.066.732.5992
Slightly volatile
Payables Turnover20.4321.5145.447
Pretty Stable
Sales General And Administrative To Revenue0.140.150.3356
Slightly volatile
Research And Ddevelopement To Revenue0.690.550.6908
Slightly volatile
Capex To Revenue0.00.04.0E-4
Slightly volatile
Cash Per Share4.954.864.7338
Slightly volatile
Days Payables Outstanding21.3222.456.9 K
Slightly volatile
Current Ratio14.1622.3718.7137
Very volatile
Receivables Turnover6.697.538.2159
Slightly volatile
Debt To Equity0.00260.00340.0013
Slightly volatile
Capex Per Share0.02210.0210.0073
Slightly volatile
Revenue Per Share1.943.821.7188
Slightly volatile
Interest Debt Per Share0.02130.02240.0172
Slightly volatile
Debt To Assets0.00250.00320.0012
Slightly volatile
Graham Number13.4415.1216.5046
Slightly volatile
Operating Cycle34.9139.2842.8724
Slightly volatile
Days Of Payables Outstanding21.3222.456.9 K
Slightly volatile
Ebt Per Ebit1.021.00.9522
Very volatile
Total Debt To Capitalization0.00260.00340.0013
Slightly volatile
Debt Equity Ratio0.00260.00340.0013
Slightly volatile
Quick Ratio14.1622.3718.7137
Very volatile
Net Income Per E B T0.770.90.9408
Slightly volatile
Cash Ratio3.84.014.8308
Slightly volatile
Days Of Sales Outstanding34.9139.2842.8724
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.910.9866
Slightly volatile
Fixed Asset Turnover1.2 K1.7 K1.3 K
Slightly volatile
Debt Ratio0.00250.00320.0012
Slightly volatile
Price Sales Ratio2.32.4246.5985
Slightly volatile
Asset Turnover0.210.410.1799
Slightly volatile
Gross Profit Margin0.30.470.3098
Slightly volatile

Atea Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap308.4 M324.6 M1.8 B
Slightly volatile

Atea Fundamental Market Drivers

Atea Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Atea Pharmaceuticals Financial Statements

Atea Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Atea Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Atea Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Atea Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue(0.90)(0.85)
Cost Of Revenue95.9 M100.7 M
Stock Based Compensation To Revenue 0.13  0.14 
Sales General And Administrative To Revenue 0.15  0.14 
Research And Ddevelopement To Revenue 0.55  0.69 
Revenue Per Share 3.82  1.94 
Ebit Per Revenue 0.35  0.37 

Pair Trading with Atea Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Atea Stock

  0.34ACB Aurora CannabisPairCorr
The ability to find closely correlated positions to Atea Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea Pharmaceuticals to buy it.
The correlation of Atea Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Atea Stock Analysis

When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.